Humaid Al-Shamsi, The Chairman of Nexomic, shared a post on LinkedIn:
“Proud to share that I will be serving as Chairman of Nexomic, an Ireland-based biotechnology company focused on advancing AI-driven biomarker discovery and multi-omic precision oncology.
At Nexomic , our mission is to transform complex genomic, transcriptomic, proteomic, and clinical data into actionable insights that can help accelerate drug discovery, enrich clinical trials, and support more personalized cancer care.
Behind this mission is an exceptional team of more than 20 bright minds, including PhDs, scientists, AI experts, bioinformaticians, and an advisory board of oncology leaders , working together to push the boundaries of cancer research.
As an oncologist, researcher, and healthcare leader, I believe the future of cancer care will be shaped by the integration of our deep clinical expertise with powerful AI and multi-omic intelligence. Our ultimate ambition is bold but clear: to contribute meaningfully to the global mission to cure cancer.
I am honored to join this journey and help build a platform that may redefine biomarker discovery, clinical trial design, and precision oncology.”
You can also read:
Prof. Humaid Al-Shamsi Appointed Chairman of Nexomic
